Noubar Afeyan and Moderna Honored with National Medal of Technology and Innovation by the President of the United States
Dr. Noubar Afeyan, Co-Founder and Board Chairman of Moderna, Founder and CEO of Flagship Pioneering was awarded the prestigious National Medal of Technology and Innovation by Dr. Arati Prabhakar, Director of the White House Office of Science and Technology Policy (OSTP), in a ceremony held at the Eisenhower Executive Office Building on January 3, 2025.
This award recognizes Moderna’s groundbreaking contributions to biotechnology, specifically the development of mRNA-based Covid-19 vaccines that a critical role in combating the global Covid-19 pandemic.
Dr. Afeyan is a visionary who co-founded FAST, Aurora and other initiatives to support Armenia’s scientific, cultural, and humanitarian development.
Join us in celebrating the recognition of Dr. Afeyan's contribution to innovation globally.
#NoubarAfeyan #Moderna #SuccessStory
—————————————————
🔥 Join 3N to stay on top of startup news
Dr. Noubar Afeyan, Co-Founder and Board Chairman of Moderna, Founder and CEO of Flagship Pioneering was awarded the prestigious National Medal of Technology and Innovation by Dr. Arati Prabhakar, Director of the White House Office of Science and Technology Policy (OSTP), in a ceremony held at the Eisenhower Executive Office Building on January 3, 2025.
This award recognizes Moderna’s groundbreaking contributions to biotechnology, specifically the development of mRNA-based Covid-19 vaccines that a critical role in combating the global Covid-19 pandemic.
Dr. Afeyan is a visionary who co-founded FAST, Aurora and other initiatives to support Armenia’s scientific, cultural, and humanitarian development.
Join us in celebrating the recognition of Dr. Afeyan's contribution to innovation globally.
#NoubarAfeyan #Moderna #SuccessStory
—————————————————
🔥 Join 3N to stay on top of startup news
❤9👍3🔥3
🧬 A huge milestone for cancer treatment
Sources: Moderna, Press-Release, Marketwatch
Moderna and Merck have announced the first-ever successful Phase 3 trial of a personalized mRNA cancer therapy.
The treatment is designed individually for each patient. After a melanoma tumor is removed, scientists sequence its DNA, identify the unique mutations of that person's cancer, and create a custom mRNA therapy that trains the immune system to recognize and destroy any remaining cancer cells.
The trial showed that, the personalized therapy significantly:
• Reduced the risk of cancer returning.
• Reduced the risk of the cancer spreading to distant organs
Investors immediately recognized the significance of the breakthrough. Moderna's stock surged by 177%.
Moderna is co-founded by Noubar Afeyan. It was created at Flagship Pioneering venture builder, growing from a scientific idea into one of the world's leading biotechnology companies.
#Moderna #Breakthrough
———
Join 3N - https://t.me/threenstartups
Sources: Moderna, Press-Release, Marketwatch
Moderna and Merck have announced the first-ever successful Phase 3 trial of a personalized mRNA cancer therapy.
The treatment is designed individually for each patient. After a melanoma tumor is removed, scientists sequence its DNA, identify the unique mutations of that person's cancer, and create a custom mRNA therapy that trains the immune system to recognize and destroy any remaining cancer cells.
The trial showed that, the personalized therapy significantly:
• Reduced the risk of cancer returning.
• Reduced the risk of the cancer spreading to distant organs
Investors immediately recognized the significance of the breakthrough. Moderna's stock surged by 177%.
Moderna is co-founded by Noubar Afeyan. It was created at Flagship Pioneering venture builder, growing from a scientific idea into one of the world's leading biotechnology companies.
#Moderna #Breakthrough
———
Join 3N - https://t.me/threenstartups
❤4